Showing 16 of 76 recruiting trials for “nasopharyngeal-teratoma”
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
RecruitingNCT05126160 ↗
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
👨⚕️ Xiaozhong Chen, Department of Radiation Oncology, Zhejiang Cancer Hospital📍 5 sites📅 Started Nov 2021View details ↗
ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
👨⚕️ Jinquan Liu, M.D, Affiliated Cancer Hospital & Institute of Guangzhou Medical University📍 1 site📅 Started Aug 2020View details ↗
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
RecruitingNCT04547673 ↗
To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
👨⚕️ Weiping Wen, Ph.D, Otolaryngology Department, First Affiliated Hospital of Sun Yat-sen University📍 3 sites📅 Started Jun 2020View details ↗
RecruitingNCT04085900 ↗
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
👨⚕️ Mingfang Ji, MD, Zhongshan People's Hospital, Guangdong, China📍 2 sites📅 Started Apr 2020View details ↗
RecruitingNCT04544969 ↗
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
← PreviousPage 4 of 4
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →